Jolie Snively

1.2k total citations
8 papers, 934 citations indexed

About

Jolie Snively is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jolie Snively has authored 8 papers receiving a total of 934 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jolie Snively's work include Immunotherapy and Immune Responses (7 papers), vaccines and immunoinformatics approaches (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Jolie Snively is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), vaccines and immunoinformatics approaches (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Jolie Snively collaborates with scholars based in United States. Jolie Snively's co-authors include Jeffrey S. Weber, Michael Yellin, Evan M. Hersh, Walter J. Urba, John D. Powderly, Geoff Nichol, Steven O’Day, Peter P. Lee, Shirley Sian and Susan Groshen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cell Proliferation.

In The Last Decade

Jolie Snively

8 papers receiving 921 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jolie Snively United States	7	682	630	276	71	62	8	934
Neil M. Barth United States	20	640 0.9×	552 0.9×	227 0.8×	177 2.5×	42 0.7×	41	953
Elizabeth Seja United States	10	770 1.1×	682 1.1×	206 0.7×	73 1.0×	68 1.1×	12	963
A. Knuth Germany	12	344 0.5×	536 0.9×	256 0.9×	102 1.4×	107 1.7×	33	816
Aurélie Durgeau France	7	661 1.0×	776 1.2×	181 0.7×	89 1.3×	26 0.4×	7	1.0k
Henning Zelba Germany	14	594 0.9×	650 1.0×	180 0.7×	53 0.7×	55 0.9×	23	883
Jessica Roelands Netherlands	14	475 0.7×	455 0.7×	311 1.1×	118 1.7×	38 0.6×	34	882
Cathy Biota France	8	628 0.9×	776 1.2×	115 0.4×	63 0.9×	21 0.3×	9	982
Robert Sanchez Rodriguez United States	6	416 0.6×	379 0.6×	104 0.4×	58 0.8×	18 0.3×	10	607
Kristine Rinn United States	11	541 0.8×	629 1.0×	281 1.0×	91 1.3×	383 6.2×	23	997
Chikara Takahashi United States	8	324 0.5×	568 0.9×	153 0.6×	39 0.5×	29 0.5×	13	779

Countries citing papers authored by Jolie Snively

Since Specialization

Citations

This map shows the geographic impact of Jolie Snively's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jolie Snively with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jolie Snively more than expected).

Fields of papers citing papers by Jolie Snively

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jolie Snively. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jolie Snively. The network helps show where Jolie Snively may publish in the future.

Co-authorship network of co-authors of Jolie Snively

This figure shows the co-authorship network connecting the top 25 collaborators of Jolie Snively. A scholar is included among the top collaborators of Jolie Snively based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jolie Snively. Jolie Snively is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Weber, Jeffrey S., Steven O’Day, Walter J. Urba, et al.. (2008). Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma. Journal of Clinical Oncology. 26(36). 5950–5956. 369 indexed citations

Weber, Jeffrey S., William D. Boswell, John W. Smith, et al.. (2008). Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma. Journal of Immunotherapy. 31(2). 215–223. 61 indexed citations

Weber, Jeffrey S., Ş. Targan, Jolie Snively, et al.. (2006). Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. Journal of Clinical Oncology. 24(18_suppl). 2510–2510. 31 indexed citations

Weber, Jeffrey S., et al.. (2005). Randomized phase II trial of melanoma peptides with Montanide ISA 51 and different doses of IL-12 with Alum for resected stages IIC/III and IV melanoma. Journal of Clinical Oncology. 23(16_suppl). 2506–2506. 3 indexed citations

Sanderson, Kristin M., Peter P. Lee, Dongxin Liu, et al.. (2004). Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma. Journal of Clinical Oncology. 23(4). 741–750. 322 indexed citations

Pullarkat, Vinod, Peter P. Lee, Susan Groshen, et al.. (2003). A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.. PubMed. 9(4). 1301–12. 34 indexed citations

Tagawa, Scott T., Peter P. Lee, Jolie Snively, et al.. (2003). Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 98(1). 144–154. 104 indexed citations

Dethlefsen, Lyle A., James A. Sorenson, & Jolie Snively. (1977). CELL LOSS FROM THREE ESTABLISHED LINES OF THE C3H MOUSE MAMMARY TUMOR: A COMPARISON OF THE ¹²⁵I‐UdR AND THE ³H‐TdR‐AUTORADIOGRAPHIC METHODS. Cell Proliferation. 10(5). 447–459. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact